# Ruijing Investment

> Ruijing Investment is a VC fund backing Biotechnology, Medical and Genetics. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 3
- Last investment: May 2022
- Lead investor: 0%
- Last updated: Aug 2026

Ruijing Investment is a VC fund focused on Biotechnology and Medical.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 67% |
| Medical | 1 | 33% |
| Genetics | 1 | 33% |
| Software | 1 | 33% |
| Health Care | 1 | 33% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 67% |
| Series A | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Dao Bio-Link | Dao Biolink is an information system integration and Internet of Things technology service provider. | $14.9M | Series A | May 25, 2022 |  |
| Gene Vector | Chengdu Genevector Biotechnology Co., Ltd. (Genevector, Genevector) is a biotechnology company engaged in the research and development of new drugs for adeno-associated virus (AAV) gene therapy. The company is committed to the development of new AAV gene therapy drugs for ophthalmic diseases, neuromuscular diseases, genetic and metabolic diseases,etc. | $3.2M | Seed | Mar 10, 2022 |  |
| NeoImmune | Universal Medicine is a technology developer in the field of immune system, dedicated to the development of key technologies for high-throughput reading and writing of T and B lymphocyte receptor profiles and their applications in clinical testing and treatment, focusing on technology developers in the field of immune system . Recently announcedthe completion of a 30 million RMB Pre-A round of strategic financing. WinX Capital is acting as a financial advisor. This round of investment was initiated by Kangsheng Global. Ruijiang Kangsheng Fund managed by Ruijiang Investment led the investment. The investors included Spark Venture Capital and Yangtze River Source Fund. This round of funds will be mainly used for the promotion of hematological tumor MRD products and the research and development of new clinical products. | $4.7M | Seed | Nov 25, 2021 |  |

3 of 3 investments shown.

## Co-investors
- [Gongshan Capital](https://shizune.co/investors/profile/gongshan-capital) — VC Fund, 2 deals together
- [Jiadao Capital](https://shizune.co/investors/profile/jiadao-capital) — VC Fund, 2 deals together
- [Kindstar Global (Beijing) Medicine Technology](https://shizune.co/investors/profile/kindstar-global-beijing-medicine-technology) — VC Fund, 2 deals together
- [Changjiang Fund](https://shizune.co/investors/profile/changjiang-fund) — VC Fund, 1 deal together
- [Ming capital](https://shizune.co/investors/profile/ming-capital) — VC Fund, 1 deal together
- [Sichuan Huisu](https://shizune.co/investors/profile/sichuan-huisu) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Ruijing Investment invest in?

Ruijing Investment invests primarily in Biotechnology, Medical and Genetics startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ruijing Investment last invest?

The most recent investment recorded for Ruijing Investment closed in May 2022. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co